Wedbush is out with its report today on Varian Medical Systems VAR, reiterating Outperform.
In a note to clients, Wedbush writes, "We added Varian Medical to the list of our top recommendations in February because of VAR's leadership in the
attractive markets for radiation oncology systems and x-ray imaging technologies
and because VAR demonstrates superior growth within the med tech industry. For
FY11, we project sales of $2.6 billion (+11%) and EPS of $3.47 (+17%). For FY12,
we project sales of $2.87 billion (+10%) and EPS of $3.90 (+12.5%). We believe
there is potential for significant upside to our numbers for next year as VAR's new oncology products, TrueBeam and proton therapy, enhance the business mix."
Wedbush maintains an $80 PT on VAR.
Shares of VAR closed Friday at $70.20, down 0.37% from Thursday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareHealth Care Equipmentvarian medical systemsWedbush
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in